261 related articles for article (PubMed ID: 15880020)
1. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
Pascual J
Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Lehmkuhl H; Hetzer R
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
[TBL] [Abstract][Full Text] [Related]
6. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
[TBL] [Abstract][Full Text] [Related]
7. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
10. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
Pascual J; Fernández AM; Marcén R; Ortuño J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with everolimus (Certican) in young renal transplant recipients.
Eris J
Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
13. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
[TBL] [Abstract][Full Text] [Related]
14. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
15. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
Vítko S; Margreiter R; Weimar W; Dantal J; Viljoen HG; Li Y; Jappe A; Cretin N;
Transplantation; 2004 Nov; 78(10):1532-40. PubMed ID: 15599319
[TBL] [Abstract][Full Text] [Related]
16. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
17. Review of the proliferation inhibitor everolimus.
Nashan B
Expert Opin Investig Drugs; 2002 Dec; 11(12):1845-57. PubMed ID: 12457444
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with everolimus (Certican) in elderly recipients: the "old-for-old" concept.
Pascual J; Marcén R; Ortuño J
Transplantation; 2005 May; 79(9 Suppl):S85-8. PubMed ID: 15880022
[TBL] [Abstract][Full Text] [Related]
19. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
20. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
Nashan B; Curtis J; Ponticelli C; Mourad G; Jaffe J; Haas T;
Transplantation; 2004 Nov; 78(9):1332-40. PubMed ID: 15548972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
